Technical Data
O8065-06
Osteoprotegerin (OPG, Osteoclastogenesis inhibitory factor, OCIF)
Description:
Osteoprotegerin (OPG, or osteoclastogenesis inhibitory factor) is a secretory glycoprotein belonging to TNF receptor superfamily. OPG consists of 401 amino acid with molecular weight of 55kD as a monomer and 110kD as a disulfide-linked dimer. Osteoprotegerin acts as a soluble factor in the regulation of bone mass and may be beneficial in the treatment of osteoporosis associated with increased osteoclast activity.

Applications:
Suitable for use in ELISA, Western blotting.

Reconstitution: Add 0.1ml of deionized water and let the lyophilized pellet dissolve completely.
Slight turbidity may occur after reconstitution, which does not affect activity
of the antibody. In this case clarify the solution by centrifugation.

Storage and Stability: May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG1,k5i340Affinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Recombinant human osteoprotegerin (OPG Fc Chimera)
Purity:
Purified by Protein G affinity chromatography.
Form
Sterile filtered and lyophilized from 1mg/ml 0.05M PBS, pH 7.2.
Specificity:
Part of the fusion protein is corresponding to amino acid sequence of human osteoprotegerin.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Simonet W.S. et al.: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997)

2. Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. : IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60.

3. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sariotakoc A, Kiotaliotac R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M. : Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004 Jan;36(1):57-66.

4. Skoumal M, Kolarz G, Woloszczuk W, Hawa G, Klingler A.: Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis. 2004 Feb;63(2):216-217.

5. Yasuda H., Shima N., Nakagawa N. et al.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteogenesis in vitro. Endocrinology 139, 1329-1337 (1998)